How to buy Recro Pharma stock

Recro Pharma Inc is a pharmaceuticals business based in the US. Recro Pharma shares (REPH) are listed on the NASDAQ and all prices are listed in US Dollars.

Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Recro Pharma stock price (NASDAQ: REPH)

Use our graph to track the performance of REPH stocks over time.

Recro Pharma shares at a glance

• Key figures

Information last updated 2022-07-17.

Latest market close	$0.79
52-week range	$0.78 - $2.19
50-day moving average more info button	$1.75
200-day moving average more info button	$1.86
Wall St. target price	$5.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-0.26

Buy Recro Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Recro Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Recro Pharma price performance over time

Historical closes compared with the close of $0.79 from 2022-05-23

1 week (2022-09-17)	N/A
1 month (2022-08-24)	N/A
3 months (2022-06-24)	N/A
6 months (2022-03-24)	N/A

1 year (2021-09-28)	-61.84%
2 years (2020-09-28)	-63.43%
3 years (2019-09-27)	11.26
5 years (2017-09-28)	9.04

Is Recro Pharma stock undervalued or overvalued?

Valuing Recro Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Recro Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Recro Pharma's EBITDA

Recro Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8 million.

The EBITDA is a measure of a Recro Pharma's overall financial performance and is widely used to measure a its profitability.

Recro Pharma financials

Revenue TTM	$75.4 million
Operating margin TTM	0.55%
Gross profit TTM	$19.8 million
Return on assets TTM	0.2%
Return on equity TTM	-81.32%
Profit margin	-15.09%
Book value	$0.90
Market capitalisation more info button	$123.2 million

TTM: trailing 12 months

Recro Pharma share dividends

We're not expecting Recro Pharma to pay a dividend over the next 12 months.

Have Recro Pharma's shares ever split?

Recro Pharma's shares were split on a 1115:1000 basis on 21 November 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1115 shares. This wouldn't directly have changed the overall worth of your Recro Pharma shares – just the quantity. However, indirectly, the new 10.3% lower share price could have impacted the market appetite for Recro Pharma shares which in turn could have impacted Recro Pharma's share price.

Recro Pharma share price volatility

Over the last 12 months, Recro Pharma's shares have ranged in value from as little as $0.775 up to $2.19. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Recro Pharma's is 1.1154. This would suggest that Recro Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Recro Pharma overview

Recro Pharma, Inc. , a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc.

Frequently asked questions

What percentage of Recro Pharma is owned by insiders or institutions?
Currently 2.45% of Recro Pharma shares are held by insiders and 54.958% by institutions. When does the fiscal year end for Recro Pharma?
Recro Pharma's fiscal year ends in December. Where is Recro Pharma based?
Recro Pharma's address is: 1 E. Uwchlan Avenue, Exton, PA, United States, 19341 What is Recro Pharma's ISIN number?
Recro Pharma's international securities identification number is: US75629F1093 What is Recro Pharma's CUSIP number?
Recro Pharma's Committee on Uniform Securities Identification Procedures number is: 75629F109